Prolonged Imiquimod Treatment and Graft-versus-Host Reaction: Histological Mimicry in the Skin Infiltration Pattern of the Monocyte-Macrophage-Dendrocyte Lineage
- 13 June 2003
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 206 (4) , 361-365
- https://doi.org/10.1159/000069958
Abstract
Factor-XIIIa-positive dendrocytes belong to the monocyte-macrophage-dendrocyte (MMD) lineage which is considered to play a pivotal role in the skin response to the immune response modifier imiquimod. The same cells are also boosted in low-grade graft-versus-host reaction (GVHR) with skin manifestations. Both conditions are characterized by specific epidermal damage. The aim of the present study was to compare them using immunohistochemistry to identify MMD subsets and other inflammatory cells in the dermis. We compared 3 cases of long-term (4, 9 and 11 months) imiquimod topical applications on normal skin, 25 low-grade GVHR controlled by immunosuppressive therapy and 25 control cases with normal skin. Compared to the normal dermis, cells of the MMD lineage were considerably boosted in the dermis of GVHR and at the imiquimod-treated sites. By contrast, only minimal accumulations of lymphocytes and Langerhans cells were disclosed in the dermis. The pattern of dermal infiltration by MMD cells was similar in GVHR and after imiquimod treatment. However, intraindividual differences in densities were obvious irrespective of the skin condition. In conclusion, there is great mimicry in the MMD involvement in the dermis during low-grade GVHR and after chronic applications of imiquimod.Keywords
This publication has 11 references indexed in Scilit:
- Imiquimod 5% Cream in the Treatment of Human Papillomavirus-16-Positive Erythroplasia of QueyratDermatology, 2002
- CCL27–CCR10 interactions regulate T cell–mediated skin inflammationNature Medicine, 2002
- Correlation between Pretreatment Levels of Interferon Response Genes and Clinical Responses to an Immune Response Modifier (Imiquimod) in Genital WartsAntimicrobial Agents and Chemotherapy, 2000
- The Immune Response Modifiers Imiquimod and R-848 Are Potent Activators of B LymphocytesCellular Immunology, 2000
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- Treatment of Diabetic RetinopathyNew England Journal of Medicine, 1999
- Regulatory Function of Factor-XIIIa-Positive Dendrocytes in Incipient Toxic Epidermal Necrolysis and Graft-versus-Host ReactionDermatology, 1999
- Self-administered Topical 5% Imiquimod Cream for External Anogenital WartsArchives of Dermatology, 1998
- Involvement of TNF-alpha secreting macrophages in lethal forms of human graft-versus-host diseaseBone Marrow Transplantation, 1997
- Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysisArchives of Dermatology, 1994